Cardiac warning over osteoporosis drug
16th April 2013
Europe's drug watchdog has moved to restrict the use of osteoporosis drug strontium ranelate (Protos), citing an increased risk of myocardial infarction compared with placebo.
A European Medicines Agency committee said data on the drug "were of concern", and would be evaluated further in an expedited, in-depth review.
In the meantime, the committee recommended avoiding strontium ranelate in people with current
